Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

Fig. 3

LS mean change in (a) SGRQ, (b) CAT and (c) CCQ from baseline for health outcomes assessments. For each health outcomes assessment, all treatment groups showed statistically significant (p < 0.05) changes from baseline at all time points. CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; ITT, intent-to-treat; LS, least squares; REV, revefenacin; SE, standard error; SGRQ, St. George’s Respiratory Questionnaire; TIO, tiotropium

Back to article page